Implantation of MDA-231 cells engineered to overexpress BMP7, or injection of recombinant BMP7, however, reduced (by 50%) the number of osteolytic lesions, overall tumor burden and the total osteolytic area [97]. This evidence concerns the gene BMP7 and neoplasm.